{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Song Q"],"pubmed_abstract":["Background
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 revised the combined chronic obstructive pulmonary disease (COPD) assessment, merging groups C and D into group E, and revised the initial inhalation therapy recommendation. We aimed to evaluate the treatment responses among different inhalation therapies in GOLD group E patients stratified by the COPD assessment test (CAT) scores and forced expiratory volume in one-second percentage of predicted (FEV1%pred).Methods
In this retrospective cohort study, we included patients with COPD registered in the Real World Research of Diagnosis and Treatment of COPD (RealDTC) study between January 2017 and June 2023. According to the GOLD 2023 report, we enrolled patients assigned to GOLD group E based on "],"journal":["Journal of global health"],"pagination":["04055"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11842004"],"repository":["biostudies-literature"],"pubmed_title":["The treatment responses among different inhalation therapies for GOLD group E patients with chronic obstructive pulmonary disease."],"pmcid":["PMC11842004"],"pubmed_authors":["Deng D","Cai S","Chen P","Li T","Song Q","Yi R","Chen Y","Zeng Y","Liu C","Liu D","Lin L","Zhang P"],"additional_accession":[]},"is_claimable":false,"name":"The treatment responses among different inhalation therapies for GOLD group E patients with chronic obstructive pulmonary disease.","description":"Background
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 revised the combined chronic obstructive pulmonary disease (COPD) assessment, merging groups C and D into group E, and revised the initial inhalation therapy recommendation. We aimed to evaluate the treatment responses among different inhalation therapies in GOLD group E patients stratified by the COPD assessment test (CAT) scores and forced expiratory volume in one-second percentage of predicted (FEV1%pred).Methods
In this retrospective cohort study, we included patients with COPD registered in the Real World Research of Diagnosis and Treatment of COPD (RealDTC) study between January 2017 and June 2023. According to the GOLD 2023 report, we enrolled patients assigned to GOLD group E based on ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-04T01:32:40.466Z","creation":"2025-04-04T01:32:40.466Z"},"accession":"S-EPMC11842004","cross_references":{"pubmed":["39977672"],"doi":["10.7189/jogh.15.04055"]}}